Approved Thursday via the FDA's Commissioner’s National Priority Voucher program, Otarmeni is the first gene therapy for ...
The Durham plant will manufacture immunology, neuroscience and oncology drugs once AbbVie finishes construction in 2028.
Roche and Zealand Pharma announced last month that their amylin analog petrelintide elicited a 9% placebo-controlled weight ...
Sanofi’s interim leadership sought on a Thursday earnings call to quell concerns that its sudden defense of Dupixent’s ...
Chief Scientific Officer Pedro Beltran will succeed Eli Wallace as CEO of BridgeBio Oncology Therapeutics, as the board eyes ...
Looking for a biopharma job in Illinois? Check out the BioSpace list of 11 companies hiring life sciences professionals like ...
This year’s American Academy of Neurology meeting included a presentation that could one day set a new treatment standard for ...
The FDA in July 2025 made publicly available over 200 complete response letters—an initiative that the investment community ...
Women and nonwhite racial/ethnic groups are still earning less in the life sciences. An industry consultant discusses the pay ...
Two of the biggest insurance providers have expressed reluctance to participate in the government’s BALANCE program that ...
In the U.S., Moderna withdrew its approval application for the combination vaccine in May last year and the timeline for ...
The deals keep rolling in, with Lilly penning a $7 billion pact for gene delivery biotech Kelonia Therapeutics and UCB taking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results